Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: Updated results of a randomised trial

J. Lacour, F. Lacour, A. Spira, M. Michelson, J. Y. Petit, G. Delage, D. Sarrazin, G. Contesso, J. Viguier

Research output: Contribution to journalArticle

Abstract

The results of a randomised trial of polyadenylic-polyuridylic acid given as an adjuvant treatment for operable breast cancer were reviewed after a mean follow up period of 87 months. Of the 300 patients included in the original trial, 145 had been allocated to conventional treatment alone and served as controls. At the time of review the overall survival of the group given polyadenylic-polyuridylic acid was significantly improved (p <0.05) as compared with that of the controls given conventional treatment alone. Significant benefit (p <0.02) was also observed among patients with evidence of disease in lymph nodes, the best results occurring in those with up to three invaded nodes, who showed a significant increase in both overall and relapse free survival. No evidence of toxicity was recorded. These findings confirm the value of polyadenylic-polyuridylic acid as adjuvant treatment for operable breast cancer. Results in an experimental model and in patients receiving the adjuvant suggested a possible role of interferon and natural killer (NK) cells in the mechanism of action.

Original languageEnglish
Pages (from-to)589-592
Number of pages4
JournalBritish Medical Journal
Volume288
Issue number6417
Publication statusPublished - 1984

Fingerprint

Poly A-U
Breast Neoplasms
Survival
Therapeutics
Natural Killer Cells
Interferons
Theoretical Models
Lymph Nodes
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lacour, J., Lacour, F., Spira, A., Michelson, M., Petit, J. Y., Delage, G., ... Viguier, J. (1984). Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: Updated results of a randomised trial. British Medical Journal, 288(6417), 589-592.

Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer : Updated results of a randomised trial. / Lacour, J.; Lacour, F.; Spira, A.; Michelson, M.; Petit, J. Y.; Delage, G.; Sarrazin, D.; Contesso, G.; Viguier, J.

In: British Medical Journal, Vol. 288, No. 6417, 1984, p. 589-592.

Research output: Contribution to journalArticle

Lacour, J, Lacour, F, Spira, A, Michelson, M, Petit, JY, Delage, G, Sarrazin, D, Contesso, G & Viguier, J 1984, 'Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: Updated results of a randomised trial', British Medical Journal, vol. 288, no. 6417, pp. 589-592.
Lacour, J. ; Lacour, F. ; Spira, A. ; Michelson, M. ; Petit, J. Y. ; Delage, G. ; Sarrazin, D. ; Contesso, G. ; Viguier, J. / Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer : Updated results of a randomised trial. In: British Medical Journal. 1984 ; Vol. 288, No. 6417. pp. 589-592.
@article{cda70e8da07c48548d4c424a4cb9549c,
title = "Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: Updated results of a randomised trial",
abstract = "The results of a randomised trial of polyadenylic-polyuridylic acid given as an adjuvant treatment for operable breast cancer were reviewed after a mean follow up period of 87 months. Of the 300 patients included in the original trial, 145 had been allocated to conventional treatment alone and served as controls. At the time of review the overall survival of the group given polyadenylic-polyuridylic acid was significantly improved (p <0.05) as compared with that of the controls given conventional treatment alone. Significant benefit (p <0.02) was also observed among patients with evidence of disease in lymph nodes, the best results occurring in those with up to three invaded nodes, who showed a significant increase in both overall and relapse free survival. No evidence of toxicity was recorded. These findings confirm the value of polyadenylic-polyuridylic acid as adjuvant treatment for operable breast cancer. Results in an experimental model and in patients receiving the adjuvant suggested a possible role of interferon and natural killer (NK) cells in the mechanism of action.",
author = "J. Lacour and F. Lacour and A. Spira and M. Michelson and Petit, {J. Y.} and G. Delage and D. Sarrazin and G. Contesso and J. Viguier",
year = "1984",
language = "English",
volume = "288",
pages = "589--592",
journal = "British Medical Journal",
issn = "0959-8146",
publisher = "BMJ Publishing Group",
number = "6417",

}

TY - JOUR

T1 - Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer

T2 - Updated results of a randomised trial

AU - Lacour, J.

AU - Lacour, F.

AU - Spira, A.

AU - Michelson, M.

AU - Petit, J. Y.

AU - Delage, G.

AU - Sarrazin, D.

AU - Contesso, G.

AU - Viguier, J.

PY - 1984

Y1 - 1984

N2 - The results of a randomised trial of polyadenylic-polyuridylic acid given as an adjuvant treatment for operable breast cancer were reviewed after a mean follow up period of 87 months. Of the 300 patients included in the original trial, 145 had been allocated to conventional treatment alone and served as controls. At the time of review the overall survival of the group given polyadenylic-polyuridylic acid was significantly improved (p <0.05) as compared with that of the controls given conventional treatment alone. Significant benefit (p <0.02) was also observed among patients with evidence of disease in lymph nodes, the best results occurring in those with up to three invaded nodes, who showed a significant increase in both overall and relapse free survival. No evidence of toxicity was recorded. These findings confirm the value of polyadenylic-polyuridylic acid as adjuvant treatment for operable breast cancer. Results in an experimental model and in patients receiving the adjuvant suggested a possible role of interferon and natural killer (NK) cells in the mechanism of action.

AB - The results of a randomised trial of polyadenylic-polyuridylic acid given as an adjuvant treatment for operable breast cancer were reviewed after a mean follow up period of 87 months. Of the 300 patients included in the original trial, 145 had been allocated to conventional treatment alone and served as controls. At the time of review the overall survival of the group given polyadenylic-polyuridylic acid was significantly improved (p <0.05) as compared with that of the controls given conventional treatment alone. Significant benefit (p <0.02) was also observed among patients with evidence of disease in lymph nodes, the best results occurring in those with up to three invaded nodes, who showed a significant increase in both overall and relapse free survival. No evidence of toxicity was recorded. These findings confirm the value of polyadenylic-polyuridylic acid as adjuvant treatment for operable breast cancer. Results in an experimental model and in patients receiving the adjuvant suggested a possible role of interferon and natural killer (NK) cells in the mechanism of action.

UR - http://www.scopus.com/inward/record.url?scp=0021264516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021264516&partnerID=8YFLogxK

M3 - Article

C2 - 6421391

AN - SCOPUS:0021264516

VL - 288

SP - 589

EP - 592

JO - British Medical Journal

JF - British Medical Journal

SN - 0959-8146

IS - 6417

ER -